Form D · Biotechnology

Maxymune Therapeutics, Inc.

Los Altos, CA · CIK 0002058052

Offering snapshot reported Jun 3, 2026 · SEC filing

Reported sold
$2.68M
Offering amount: $4.5M
Investors reported
15
Form D · investor count
Minimum accepted
$10K
Reported outside-investor minimum
First sale
Feb 11, 2025
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.34M$2.68MFeb 28, 2025: $850,000.00Feb 28, 2025Jun 3, 2026: $2,675,000.00Jun 3, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$850,000 → $2,675,000
  • Reported investors8 → 15

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 3, 2026Amendment$2,675,000$1,825,000vs Feb 28, 202515SEC filing
Feb 28, 2025Initial$850,000No comparison8SEC filing

Offering details

Securities
Option to acquire
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-539494

Source: Form D, filed Jun 3, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Tatjana Naranda Director, Executive
Gordon Ringold Director, Executive
Neil Solomons Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
95 Main St. Suite 9
Los Altos, CA, 94022